Key takeaways
- Founded in Hyderabad in 1999 on the bet that global pharma would outsource discovery research to India.
- It built medicinal chemistry, biology and DMPK, then development and manufacturing, becoming a full CRDMO.
- TPG Capital took a controlling stake in 2018, funding the build-out.
- Its December 2024 IPO was subscribed 11x; by FY25 revenue topped ₹1,600 crore as commercial CDMO scaled.
- 1999 Krishnam Raju Datla founds Sai Life Sciences in Hyderabad, betting global pharma will increasingly outsource its discovery research to India.
- 2005 It builds out medicinal-chemistry, biology and DMPK capabilities.
- 2014 It adds development and manufacturing services, becoming a Contract Research, Development and Manufacturing Organisation (CRDMO).
- 2018 TPG Capital invests for a controlling stake.
- 2022 Commercial manufacturing scales as customer molecules progress through clinical trials.
- Dec 2024 Its IPO at ₹549 is subscribed 11x and lists at a strong premium.
- 2025 Western pharma’s outsourcing of late-stage molecules to India accelerates as the China-plus-one supply-chain shift continues.
- FY25 Revenue tops ₹1,600 crore as CDMO revenue scales.
- 2025–2026 Commercial CDMO revenue compounds and margins expand on the mix shift, with commercial molecules flagged as the primary growth driver.
- 2026 Sai Life stands as one of the cleanest listed Indian CRDMO plays.
Sai Life Sciences built capability for twenty years before the public markets paid for it. A TPG investment kept the company funded through the build phase, and the 2024 IPO finally gave Indian investors a way to own the contract-research-and-manufacturing theme at scale, just as Western pharma accelerated its outsourcing to India. Here is the journey, year by year.
The pattern is the point
Sai built capability for twenty years before the public markets paid for it; the TPG investment kept it funded through the build phase, and the IPO finally gave Indian investors a way to own the CRDMO theme at scale. The capability built before the theme is the capability paid for after it, a recurring shape across these journeys.
